 |
|
|
Important Notice: The Forum does not endorse any medical
product or therapy. ALL medications and supplements
should be taken ONLY under the supervision of a physician,
due to the possibility of side-effects, drug interactions,
etc.
|
Drug:
|
Galantamine
|
|
Clinical Trial ID:
|
NCT00176423
|
|
Mode of action:
|
AChE-inhibitor, nAChR modulator
|
|
Phase:
|
POC Failed
|
|
Company:
|
University of Maryland
|
|
Note:
|
Add-on for cognitive deficiency shows very moderate effects
on negative symptoms but not on cognition
|
Conley RR, Boggs DL, Kelly DL, McMahon RP, Dickinson D,
Feldman S, Ball MP, Buchanan RW. The effects of galantamine
on psychopathology in chronic stable schizophrenia. Clin
Neuropharmacol. 2009 Mar-Apr;32(2):69-74. Abstract
Friedman JI. Cholinergic targets for cognitive enhancement
in schizophrenia: focus on cholinesterase inhibitors and
muscarinic agonists. Psychopharmacology (Berl) . 2004 Jun 1
; 174(1):45-53. Abstract
|
|
|
|
|
Text Size 
See our most recent Schizophrenia Bulletin theme Webinar: